Prevalence and risk factors of retinopathy of prematurity in Kazakhstan: A retrospective study
DOI:
https://doi.org/10.37800/RM.2.2025.500Keywords:
retinopathy of prematurity, prematurity, risk factors, oxygen therapy, neonatal screeningAbstract
Relevance: Retinopathy of prematurity (ROP) is considered to be the main reason for eyesight deficiency and complete vision loss in preterm babies globally. It is essential to be aware of the frequency and contributing conditions to be ready to provide timely treatment. This retrospective research explores ROP prevalence, investigates important mother- and infant-related predisposing factors, and analyses the medical consequences of impacted newborns. The outcomes aim to improve neonatal treatment approaches and guide state-level screening protocols.
The study aimed to identify the prevalence and risk factors of retinopathy of prematurity to enhance neonatal medical practices and lower the incidence of ROP-induced blindness.
Materials and Methods: This retrospective study included medical histories of 367 infants born from 2021 to 2022 at the Modern Multidisciplinary Medical Center “Center for Perinatology and Pediatric Cardiac Surgery” (Almaty, Kazakhstan). The prevalence rates, risk factors, and clinical outcomes of retinopathy of prematurity were analyzed using descriptive and inferential statistics.
Results: ROP was found in 25% of the newborns; the disease more often affected Zone III (45%). The majority of premature infants were diagnosed with Stage 2 retinopathy (85,7%). Key risk factors included bradycardia (p <0.001), congenital pneumonia (p <0.001), hemorrhagic syndrome (p <0.001), and neonatal jaundice (p <0.001).
Conclusion: ROP prevalence varies significantly across regions, with early detection and management critical to reducing the burden of blindness. Further studies are needed to explore regional differences and optimize screening protocols.
References
García H, Villasis-Keever MA, Zavala-Vargas G, Bravo-Ortiz JC, Pérez-Méndez A, Escamilla-Núñez A. Global Prevalence and Severity of Retinopathy of Prematurity over the Last Four Decades (1985-2021): A Systematic Review and Meta-Analysis. Arch Med Res. 2024;55(2):102967. https://doi.org/10.1016/j.arcmed.2024.102967
Wickramasinghe LC, Lau M, Deliyanti D, Gottschalk TA, van Wijngaarden P, Talia D, Johnson C, Wilkinson-Berka JL, Tsantikos E, Hibbs ML. Lung and Eye Disease Develop Concurrently in Supplemental Oxygen-Exposed Neonatal Mice. Am J Pathol. 2020;190(9):1801–1812. https://doi.org/10.1016/j.ajpath.2020.05.016
Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Paul Chan RV, Berrocal A, Binenbaum G, Blair M, Peter Campbell J, Capone A Jr, Chen Y, Dai S, Ells A, Fleck BW, Good WV, Elizabeth Hartnett M, Holmstrom G, Kusaka S, Kychenthal A, Lepore D, Lorenz B, Martinez-Castellanos MA, Özdek Ş, Ademola-Popoola D, Reynolds JD, Shah PK, Shapiro M, Stahl A, Toth C, Vinekar A, Visser L, Wallace DK, Wu WC, Zhao P, Zin A. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology.2021;128(10):e51–e68. https://doi.org/10.1016/j.ophtha.2021.05.031
Chiang MF, Quinn GE, Fielder AR, Ostmo SR, Chan RV, Berrocal A, et al. International Classification of Retinopathy of Prematurity, Third Edition. Ophthalmology. 2021;128(10):e51-e68. https://doi.org/10.1016/j.ophtha.2021.05.031
Perrone S, Lembo C, Giordano M, Petrolini C, Cannavò L, Gitto E. Molecular mechanisms of oxidative stress-related neonatal jaundice. J Biochem Mol Toxicol. 2023;37(6):e23349. https://doi.org/10.1002/jbt.23349
Mutlu FM, Altinsoy HI, Mumcuoglu T, Kerimoglu H, Kiliç S, Kul M, Sarici SU, Alpay F. Screening for retinopathy of prematurity in a tertiary care newborn unit in Turkey: frequency, outcomes, and risk factor analysis. J Pediatr Ophthalmol Strabismus. 2008;45(5):291-298. https://doi.org/10.3928/01913913-20080901-12
Gonçalves E, Násser LS, Martelli DR, Alkmim IR, Mourão TV, Caldeira AP, Martelli H Jr. Incidence and risk factors for retinopathy of prematurity in a Brazilian reference service. Sao Paulo Med J. 2014;132(2):85-91. https://doi.org/10.1590/1516-3180.2014.1322544
Bhatnagar A, Skrehot HC, Bhatt A, Herce H, Weng CY. Epidemiology of Retinopathy of Prematurity in the US From 2003 to 2019. JAMA Ophthalmol. 2023;141(5):479-485. https://doi.org/10.1001/jamaophthalmol.2023.0809
Blazon MN, Rezar-Dreindl S, Wassermann L, Neumayer T, Berger A, Stifter E. Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in a Tertiary Care Center. J Clin Med. 2024;13(22):6926. https://doi.org/10.3390/jcm13226926
Talkad SR, Zackula R. Strategies to Prevent Severe Retinopathy of Prematurity: A 2020 Update and Meta-analysis. NeoReviews. 2020;21(4):e249-e263. https://doi.org/10.1542/neo.21-4-e249
Ozaki K, Kato D, Ikegami A, Nishina S, Yokoi T, Azuma N. Maternal immune activation induces sustained changes in fetal microglia motility. Sci Rep. 2020;10:21378. https://doi.org/10.1038/s41598-020-78294-2
Lin YW, Chen SN, Muo CH, Sung FC, Lin MH. Risk of Retinopathy of Prematurity in Preterm Births with Respiratory Distress Syndrome: A Population-Based Cohort Study in Taiwan. Int J Gen Med. 2022;15:2149-2162. https://doi.org/10.2147/IJGM.S344056
Wickramasinghe LC, van Wijngaarden P, Tsantikos E, Hibbs ML. The immunological link between neonatal lung and eye disease. Clin Transl Immunol. 2021;10(8):e1322. https://doi.org/10.1002/cti2.1322
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 С.С. Сайранкызы, А.С. Жарылкасынова, Н.С. Божбанбаева, О.О. Ан, Р.А. Майкупова, А.Ж. Садыкова, Н.А. Сагатбаева
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The articles published in this Journal are licensed under the CC BY-NC-ND 4.0 (Creative Commons Attribution – Non-Commercial – No Derivatives 4.0 International) license, which provides for their non-commercial use only. Under this license, users have the right to copy and distribute the material in copyright but are not permitted to modify or use it for commercial purposes. Full details on the licensing are available at https://creativecommons.org/licenses/by-nc-nd/4.0/.
